0001636282-26-000109.txt : 20260903 0001636282-26-000109.hdr.sgml : 20260903 20260903213344 ACCESSION NUMBER: 0001636282-26-000109 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260901 FILED AS OF DATE: 20260903 DATE AS OF CHANGE: 20260903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burrows Scott L CENTRAL INDEX KEY: 0001853327 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261360021 MAIL ADDRESS: STREET 1: C/O SPYRE THERAPEUTICS, INC. STREET 2: 221 CRESCENT STREET, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1788485622.xml FORM 4 X0609 4 2026-09-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001853327 Burrows Scott L false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer 1 Common Stock 2026-09-01 4 M 0 7500 14.50 A 105494 D Common Stock 2026-09-01 4 S 0 900 86.25 D 104594 D Common Stock 2026-09-01 4 S 0 4384 87.11 D 100210 D Common Stock 2026-09-01 4 S 0 2016 88.03 D 98194 D Common Stock 2026-09-01 4 S 0 200 89.04 D 97994 D Common Stock 2026-09-02 4 S 0 18232 89.35 D 79762 D Stock Option (Right to Buy) 14.50 2026-09-01 4 M 0 7500 0 D 2033-09-01 Common Stock 7500 337357 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person. Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-09-03